Monoclonal Antibody Therapy in Parkinson's Disease - The End?

Affiliations

¹ From Translational Health Sciences, Bristol Medical School, University of Bristol, and the Movement Disorders Group, Bristol Brain Centre, Southmead Hospital, North Bristol NHS Trust - both in Bristol, United Kingdom.

Editorial

Alan Whone. N Engl J Med. 2022.

. 2022 Aug 4;387(5):466-467.

doi: 10.1056/NEJMe2207681.

¹ From Translational Health Sciences, Bristol Medical School, University of Bristol, and the Movement Disorders Group, Bristol Brain Centre, Southmead Hospital, North Bristol NHS Trust - both in Bristol, United Kingdom.

No abstract available

Comment on

Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.